EKF Diagnostics (LON:EKF) Announces Earnings Results

EKF Diagnostics (LON:EKF) announced its quarterly earnings data on Tuesday. The company reported GBX 1.38 ($0.02) EPS for the quarter, Digital Look Earnings reports. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%.

EKF Diagnostics Stock Down 1.1 %

Shares of EKF stock traded down GBX 0.25 ($0.00) during mid-day trading on Thursday, hitting GBX 21.75 ($0.28). The company’s stock had a trading volume of 3,806,497 shares, compared to its average volume of 568,946. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60. EKF Diagnostics has a 52-week low of GBX 18.40 ($0.24) and a 52-week high of GBX 33.80 ($0.44). The stock has a market cap of £96.67 million, a price-to-earnings ratio of 20.24 and a beta of 0.57. The business has a 50-day moving average price of GBX 23.23 and a 200 day moving average price of GBX 25.85.

Insider Buying and Selling

In other news, insider Gavin T. Jones purchased 50,000 shares of the stock in a transaction dated Tuesday, March 25th. The shares were purchased at an average cost of GBX 22 ($0.28) per share, with a total value of £11,000 ($14,162.48). 5.24% of the stock is owned by corporate insiders.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on:

? Point-of-Care analysers in the key areas of Hematology and Diabetes

? Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.